Funding News Edition: January 11, 2017 See more articles in this edition
In December, Congress passed and the President signed into law the 21st Century Cures Act.
As you may have heard, the new law establishes an NIH Innovation Account, authorizing $4.796 billion to fund several large projects over the next 10 years. Those projects include the Precision Medicine Initiative, the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative, and the Cancer Moonshot initiative, as well as clinical research in regenerative medicine.
More broadly, the law set NIH reauthorization amounts for the next three fiscal years (FYs) as follows:
- FY 2018 – $34.851 billion
- FY 2019 – $35.585 billion
- FY 2020 – $36.472 billion
See Background on NIAID Funding Opportunity Planning and the Budget Cycle to learn how authorizations correspond with appropriations.
The law also simplifies various administrative processes and codifies several NIH policies. For example, the Cures Act exempts NIH from the requirements of the Paperwork Reduction Act for voluntary collection of information during the conduct of research. It also authorizes the NIH director to require recipients of NIH awards to share scientific data generated from NIH-funded research.
To learn more about how the bill will impact NIH, we encourage you to read The 21st Century Cures Act—A View From the NIH, a Perspective published in the New England Journal of Medicine on December 13, 2016.